Evidence map›Paper›PMID 30877711›Full record

ArticleDiabetes & metabolism journal2019

Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.

Jung Beom Seo, Yeon Kyung Choi, Hye In Woo, Yun A Jung, Sungwoo Lee, Seunghyeong Lee, Mihyang Park, In Kyu Lee, Gwon Soo Jung, Keun Gyu Park

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & metabolism journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Article
  18. Article
  19. Review
  20. Inflammasome as an Effective Platform for Fibrosis Therapy.Journal of inflammation research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jung Beom Seo *Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID 0000-0003-2568-478X
Yeon Kyung Choi *Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID 0000-0003-0996-6437
Hye In WooDivision of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Yun A JungDivision of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Sungwoo LeeNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea.
Seunghyeong LeeDepartment of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Korea.
Mihyang ParkDepartment of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Korea.
In Kyu LeeDivision of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Gwon Soo JungNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea. gsjung@dgmif.re.kr.ORCID 0000-0002-9640-8558
Keun Gyu ParkDivision of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. kpark@knu.ac.kr.ORCID 0000-0002-8403-1298
Kyungpook National University · KRDaegu-Gyeongbuk Medical Innovation Foundation · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe hypoglycemic drugs dipeptidyl peptidase-4 (DPP-4) inhibitors have proven protective effects on diabetic kidney disease, including renal fibrosis. Although NOD-like receptor protein 3 (NLRP3) inflammasome activation is known to play an important role in the progression of renal fibrosis, the impact of DPP-4 inhibition on NLRP3-mediated inflammation while ameliorating renal fibrosis has not been fully elucidated. Here, we report that the renoprotective effect of gemigliptin is associated with a reduction in NLRP3-mediated inflammation in a murine model of renal fibrosis.

methodsWe examined the effects of gemigliptin on renal tubulointerstitial fibrosis induced in mice by unilateral ureteral obstruction (UUO). Using immunohistochemical and Western blot analysis, we quantitated components of the NLRP3 inflammasome in kidneys with and without gemigliptin treatment, and

resultsImmunohistological examination revealed that gemigliptin ameliorated UUO-induced tubular atrophy and renal fibrosis. Gemigliptin-treated kidneys showed a reduction in levels of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, and interleukin-1β, which had all been markedly increased by UUO. In line with the

conclusionThe present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NLRP3 inflammasome activation.

Indexed as

Administration, OralAnimalsCell LineDiabetic NephropathiesDipeptidyl-Peptidase IV InhibitorsDown-RegulationFibrosisHumansInflammasomesInflammationKidney Tubules, ProximalMiceMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinPiperidonesProtective AgentsDipeptidyl-Peptidase IV InhibitorsInflammasomesLC15-0444NLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanNlrp3 protein, mousePiperidonesProtective AgentsPyrimidinesTransforming Growth Factor betaDipeptidyl-peptidase IV inhibitorsFibrosisInflammasomesKidneyLC15-0444 (Gemigliptin)

Identifiers

PMID30877711
PMCPMC6943262
OpenAlexW2922070100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.